The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Abstract
PURPOSE: The trial was undertaken to determine (1) the relative efficacy/toxicity of two commonly used combination chemotherapy regimens in patients with extensive small-cell lung cancer (SCLC) and (2) whether the rapid alternation of these two regimens could provide superior therapeutic results compared with either regimen alone. PATIENTS AND METHODS: In this phase III trial, 437 eligible patients were stratified by performance status (PS) and sex and were randomly assigned to receive either 12 weeks of cisplatin and etoposide (EP); 18 weeks of cyclophosphamide, doxorubicin, and vincristine (CAV); or 18 weeks of alternation of these two regimens (CAV/EP). RESULTS: There were no significant differences in treatment outcome for EP, CAV, or CAV/EP in terms of response rate (61%, 51%, 59%, respectively), complete response rate (10%, 7%, 7%, respectively), or median survival (8.6 months, 8.3 months, 8.1 months, respectively), with a non-statistically significant trend toward a longer median time to progression with alternating therapy (4.3 months, 4.0 months, 5.2 months, respectively). Crossover second-line chemotherapy given at progression produced low response rates and short survival, regardless of the regimen used. Myelosuppression was the dose-limiting toxicity for all patients, although the pattern and severity differed among the treatment arms. CONCLUSIONS: The combination regimens EP and CAV can be considered equivalently effective induction therapies in extensive SCLC, and these two regimens are, to some degree, crossresistant. Alternating therapy provides no therapeutic advantage compared with the use of either of these regimens alone and should not be considered as standard treatment in this clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Rationale for the use of alternating non-cross-resistant chemotherapy.
Goldie, J. H., Coldman, A. J., & Ga, G. (1982) · PubMed · Cited by 539
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
Evans, W. K., Shepherd, F. A., Feld, R., Osoba, D., Dang, P., & Deboer, G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.11.1471 · Cited by 317
EVANS, W. K., FELD, R., MURRAY, N., WILLAN, A., OSOBA, D., SHEPHERD, F. A., CLARK, D. A., LEVITT, M., MacDONALD, A., WILSON, K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-451 · Cited by 223
Einhorn, L. H., Crawford, J., Birch, R., Omura, G., Johnson, D. H., & Greco, F. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.3.451 · Cited by 123
Self-citationChemotherapy in non-small cell lung cancer: results of recent trials.
Loehrer, P. J., Einhorn, L. H., & Fa, G. (1988) · PubMed · Cited by 67
Self-citationGoodman, G. E., Crowley, J. J., Blasko, J. C., Livingston, R. B., BECK, T. M., Demattia, M. D., & Bukowski, R. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.39 · Cited by 67
Hong, W. K., Nicaise, C., Lawson, R. D., Maroun, J. A., Comis, R. L., Speer, J. F., Luedke, D. W., Hurtubise, M., Lanzotti, V. J., & Goodlow, J. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.450 · Cited by 58
Self-citationWolf, M., Pritsch, M., Drings, P., Hans, K., Schroeder, M. P., Flechtner, H., Heim, M., Hruska, D., Mende, S., & Becker, H. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.614 · Cited by 51
Combination chemotherapy in small cell lung carcinoma: A randomized study of two intensive regimens
Lowenbraun, S., Birch, R., Buchanan, R., Krauss, S., Durant, J. R., Perez, C. A., Mill, W. B., Vollmer, R. T., & Ogden, L. L. (1984) · Cancer · doi:10.1002/1097-0142(19841201)54:11<2344::aid-cncr2820541106>3.0.co;2-c · Cited by 46
Cited by
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Self-citationNoda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Metadata
- Authors
- Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., & Broun, G. O.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-02
- Volume
- 10
- Issue
- 2
- Pages
- 282-291
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123767004
- Cited by
- 556
- References
- 11
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.